trending Market Intelligence /marketintelligence/en/news-insights/trending/itryL5Ch_u6m4ILdie6IrQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck and Incyte's combo therapy shows promise against lung cancer in trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merck and Incyte's combo therapy shows promise against lung cancer in trial

An early stage clinical trial of a combination of cancer medicines from Merck & Co. Inc. and Incyte Corp. produced a 35% overall response rate among 40 patients with advanced non-small cell lung cancer.

The data are a strong basis for continuing development of the combination as an initial therapy against lung cancer, the companies said in a release issued June 3 during the annual meeting of the American Society of Clinical Oncology in Chicago.

Two of the patients whose cancer responded to the therapy, consisting of Merck's U.S.-approved Keytruda and Incyte's experimental epacadostat, saw their tumors disappear, while 12 patients saw their tumors shrink. In addition, 10 of the 14 responses to the treatment are continuing, with some continuing after more than 76 weeks, the companies said.

Five percent of patients experienced treatment-related side effects that led to discontinuation of treatment.

Patients with both higher and lower levels of the biomarker PD-L1 demonstrated responses to the combination therapy.

Both Keytruda and epacadostat harness the body's natural immune response by inhibiting molecules that typically restrain the immune system. Keytruda inhibits the PD-1 protein, while epacadostat inhibits the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1, or IDO1.

Keytruda is already approved to treat non-small cell lung cancer. But Food and Drug Administration approval of the combination therapy would be Keytruda's first approval against the disease in combination with another immunotherapy.

Analysts expect sales of the drug to more than double in 2017 to exceed $3 billion.